Oncolytic Viruses in Cancer Immunotherapy
Advanced Therapeutics · 2024-07 · 7 (7)
DOI: 10.1002/adtp.202300445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Therapeutics, online erschienen am 22.05.2024. Verfasst von Xiao Li und 1 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 202 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Oncolytic viruses are novel and promising therapeutic regimens that promote antitumor efficacy through multimode mechanisms, including direct lysis of tumor cells, release of the tumor antigens and danger signals, induction of immunological cell death, activation of innate, and adaptive immune response. In addition, oncolytic viruses can be engineered to express virus‐centered and immune‐centered therapeutic transgenes, further transforming the “cold” tumor into “hot” and enhancing the oncolytic efficacy. Several oncolytic viruses are engineered and widely used as potential therapeutic agents for many cancers and the therapeutic strategies and effectiveness vary among different types of oncolytic viruses. Finally, oncolytic viruses‐based combination immunotherapy is practiced in preclinical and clinical studies, and indicates that combination of oncolytic viruses with conventional therapy or immunomodulatory agents exerts favorable antitumor efficacy.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., & Cheng, Z. (2024). Oncolytic Viruses in Cancer Immunotherapy. Advanced Therapeutics, 7(7). https://doi.org/10.1002/adtp.202300445
Vancouver
Li X, Cheng Z. Oncolytic Viruses in Cancer Immunotherapy. Advanced Therapeutics. 2024;7(7). doi:10.1002/adtp.202300445
BibTeX
@article{Li2024,
author = {Li, Xiao and Cheng, Zhongping},
title = {Oncolytic Viruses in Cancer Immunotherapy},
journal = {Advanced Therapeutics},
year = {2024},
volume = {7},
number = {7},
doi = {10.1002/adtp.202300445}
}
EUVIMED